Advertisement

The Role of Tauroursodeoxycholic Acid on Dedifferentiation of Vascular Smooth Muscle Cells by Modulation of Endoplasmic Reticulum Stress and as an Oral Drug Inhibiting In-Stent Restenosis

  • Hangqi Luo
  • Changzuan Zhou
  • Jufang Chi
  • Sunlei Pan
  • Hui Lin
  • Feidan Gao
  • Tingjuan Ni
  • Liping Meng
  • Jie Zhang
  • Chengjian Jiang
  • Zheng Ji
  • Haitao Lv
  • Hangyuan GuoEmail author
ORIGINAL ARTICLE
  • 37 Downloads

Abstract

Purpose

The role of endoplasmic reticulum (ER) stress in cardiovascular disease is now recognized. Tauroursodeoxycholic acid (TUDCA) is known to have cardiovascular protective effects by decreasing ER stress. This study aimed to assess the ability of TUDCA to decrease ER stress, inhibit dedifferentiation of vascular smooth muscle cells (VSMCs), and reduce in-stent restenosis.

Methods

The effect of TUDCA on dedifferentiation of VSMCs and ER stress was investigated in vitro using wound-healing assays, MTT assays, and western blotting. For in vivo studies, 18 rabbits were fed an atherogenic diet to induce atheroma formation. Bare metal stents (BMS), BMS+TUDCA or Firebird stents were implanted in the left common carotid artery. Rabbits were euthanized after 28 days and processed for scanning electron microscope (SEM), histological examination (HE), and immunohistochemistry.

Results

In vitro TUDCA (10–1000 μmol/L) treatment significantly inhibited platelet-derived growth factor (PDGF)-BB-induced proliferation and migration in VSMCs in a concentration-dependent manner and decreased ER stress markers (IRE1, XBP1, KLF4, and GRP78). In vivo, we confirmed no significant difference in neointimal coverage on three stents surfaces; neointimal was significantly lower with BMS+TUDCA (1.6 ± 0.2 mm2) compared with Firebird (1.90 ± 0.1 mm2) and BMS (2.3 ± 0.1 mm2). Percent stenosis was lowest for BMS+TUDCA, then Firebird, and was significantly higher with BMS (28 ± 4%, 35 ± 7%, 40 ± 1%; respectively; P < 0.001). TUDCA treatment decreased ER stress in the BMS+TUDCA group compared with BMS.

Conclusions

TUDCA inhibited dedifferentiation of VSMCs by decreasing ER stress and reduced in-stent restenosis, possibly through downregulation of the IRE1/XBP1 signaling pathway.

Keywords

Vascular smooth muscle cells Tauroursodeoxycholic acid Dedifferentiation In-stent restenosis Endoplasmic reticulum stress IRE1/XBP1 signaling pathway 

Notes

Acknowledgments

The authors thank the Faculty of Agriculture, Life and Environment Science at Zhejiang University for their valuable technical assistance. We thank Sarah Bubeck, Ph.D., from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Funding

This study was supported by Co construction of Provincial Department key project (Grant No. WKJ-ZJ-1729) and Zhejiang Science and Technology Department Animal Experimental Research Project (2017C37141).

Compliance with Ethical Standards

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.CrossRefGoogle Scholar
  2. 2.
    Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65:2496–507.CrossRefGoogle Scholar
  3. 3.
    Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J. 2009;73:615–21.CrossRefGoogle Scholar
  4. 4.
    Kaul U, Bangalore S, Seth A, Arambam P, Abhaichand RK, Patel TM, et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes. N Engl J Med. 2015;373:1709–19.CrossRefGoogle Scholar
  5. 5.
    de la Torre Hernandez JM, Alfonso F, Martin Yuste V, Sanchez Recalde A, Jimenez Navarro MF, Perez de Prado A, et al. Comparison of paclitaxel and everolimus-eluting stents in st-segment elevation myocardial infarction and influence of thrombectomy on outcomes. Estrofa-im study. Rev Esp Cardiol (Engl Ed). 2014;67:999–1006.CrossRefGoogle Scholar
  6. 6.
    Pan M, Burzotta F, Trani C, Medina A, Suarez de Lezo J, Niccoli G, et al. Three-year follow-up of patients with bifurcation lesions treated with sirolimus- or everolimus-eluting stents: seaside and corpal cooperative study. Rev Esp Cardiol (Engl Ed). 2014;67:797–803.CrossRefGoogle Scholar
  7. 7.
    Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333–42.CrossRefGoogle Scholar
  8. 8.
    Zhang DP, Ge YG, Ni ZH. Very late angiographic stent thrombosis after sirolimus-eluting stent implantation at 54 months. Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36:176–7.PubMedGoogle Scholar
  9. 9.
    Takahashi S, Kaneda H, Tanaka S, Miyashita Y, Shiono T, Taketani Y, et al. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J. 2007;71:226–8.CrossRefGoogle Scholar
  10. 10.
    Kuriyama N, Kobayashi Y, Nakama T, Mine D, Nishihira K, Shimomura M, et al. Late restenosis following sirolimus-eluting stent implantation. JACC Cardiovasc Interv. 2011;4:123–8.CrossRefGoogle Scholar
  11. 11.
    Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-cypher registry. Circulation. 2012;125:584–91.CrossRefGoogle Scholar
  12. 12.
    Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59:2051–7.CrossRefGoogle Scholar
  13. 13.
    Shah R, Ramos-Bondy B, Mizeracki A. Risk of stent thrombosis with bioresorbable vascular scaffolds. Lancet. 2016;387:1903.CrossRefGoogle Scholar
  14. 14.
    Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The udca-pbc study group. N Engl J Med. 1994;330:1342–7.CrossRefGoogle Scholar
  15. 15.
    Rudolph G, Endele R, Senn M, Stiehl A. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology. 1993;17:1028–32.CrossRefGoogle Scholar
  16. 16.
    Luketic VA, Sanyal AJ. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease. Gastroenterologist. 1994;2:74–9.PubMedGoogle Scholar
  17. 17.
    Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Hur J, et al. New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of mmp-9. Arterioscler Thromb Vasc Biol. 2009;29:472–9.CrossRefGoogle Scholar
  18. 18.
    Makino I, Tanaka H. From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroenterol Hepatol. 1998;13:659–64.CrossRefGoogle Scholar
  19. 19.
    Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3:58–69.CrossRefGoogle Scholar
  20. 20.
    Cho JG, Lee JH, Hong SH, Lee HN, Kim CM, Kim SY, et al. Tauroursodeoxycholic acid, a bile acid, promotes blood vessel repair by recruiting vasculogenic progenitor cells. Stem Cells. 2015;33:792–805.CrossRefGoogle Scholar
  21. 21.
    Ma J, Nakajima T, Iida H, Iwasawa K, Terasawa K, Oonuma H, et al. Inhibitory effects of ursodeoxycholic acid on the induction of nitric oxide synthase in vascular smooth muscle cells. Eur J Pharmacol. 2003;464:79–86.CrossRefGoogle Scholar
  22. 22.
    Lee WY, Han SH, Cho TS, Yoo YH, Lee SM. Effect of ursodeoxycholic acid on ischemia/reperfusion injury in isolated rat heart. Arch Pharm Res. 1999;22:479–84.CrossRefGoogle Scholar
  23. 23.
    Kim SY, Kwon YW, Jung IL, Sung JH, Park SG. Tauroursodeoxycholate (tudca) inhibits neointimal hyperplasia by suppression of erk via pkcalpha-mediated mkp-1 induction. Cardiovasc Res. 2011;92:307–16.CrossRefGoogle Scholar
  24. 24.
    Fan L, Chen LL, Lin CG, Peng YF, Zheng XC, Luo YK, et al. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions. Chin Med J. 2008;121:1518–23.PubMedGoogle Scholar
  25. 25.
    Gao Z, Yang YJ, Chen JL, Qiao SB, Xu B, Qin XW, et al. Effects of sirolimus-eluting stent and the paclitaxel-eluting stent: a three-year follow-up study. Zhonghua Yi Xue Za Zhi. 2008;88:1811–4.PubMedGoogle Scholar
  26. 26.
    Gao H, Yan HB, Zhu XL, Li N, Ai H, Wang J, et al. Firebird sirolimus eluting stent versus bare mental stent in patients with st-segment elevation myocardial infarction. Chin Med J. 2007;120:863–7.PubMedGoogle Scholar
  27. 27.
    Iaconetti C, De Rosa S, Polimeni A, Sorrentino S, Gareri C, Carino A, et al. Down-regulation of mir-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc Res. 2015;107:522–33.CrossRefGoogle Scholar
  28. 28.
    Fitzgerald TN, Shepherd BR, Asada H, Teso D, Muto A, Fancher T, et al. Laminar shear stress stimulates vascular smooth muscle cell apoptosis via the akt pathway. J Cell Physiol. 2008;216:389–95.CrossRefGoogle Scholar
  29. 29.
    Palumbo R, Gaetano C, Melillo G, Toschi E, Remuzzi A, Capogrossi MC. Shear stress downregulation of platelet-derived growth factor receptor-beta and matrix metalloprotease-2 is associated with inhibition of smooth muscle cell invasion and migration. Circulation. 2000;102:225–30.CrossRefGoogle Scholar
  30. 30.
    Garanich JS, Pahakis M, Tarbell JM. Shear stress inhibits smooth muscle cell migration via nitric oxide-mediated downregulation of matrix metalloproteinase-2 activity. Am J Physiol Heart Circ Physiol. 2005;288:H2244–52.CrossRefGoogle Scholar
  31. 31.
    Wang CF, Yuan JR, Qin D, Gu JF, Zhao BJ, Zhang L, et al. Protection of tauroursodeoxycholic acid on high glucose-induced human retinal microvascular endothelial cells dysfunction and streptozotocin-induced diabetic retinopathy rats. J Ethnopharmacol. 2016;185:162–70.CrossRefGoogle Scholar
  32. 32.
    Chen S, Liu B, Kong D, Li S, Li C, Wang H, et al. Atorvastatin calcium inhibits phenotypic modulation of pdgf-bb-induced vsmcs via down-regulation the akt signaling pathway. PLoS One. 2015;10:e0122577.CrossRefGoogle Scholar
  33. 33.
    Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res. 2008;38:123–31.PubMedGoogle Scholar
  34. 34.
    Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:318–28.CrossRefGoogle Scholar
  35. 35.
    Hua Y, Kandadi MR, Zhu M, Ren J, Sreejayan N. Tauroursodeoxycholic acid attenuates lipid accumulation in endoplasmic reticulum-stressed macrophages. J Cardiovasc Pharmacol. 2010;55:49–55.CrossRefGoogle Scholar
  36. 36.
    Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce er stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137–40.CrossRefGoogle Scholar
  37. 37.
    Chen Y, Liu CP, Xu KF, Mao XD, Lu YB, Fang L, et al. Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic reticulum stress and apoptosis induced by advanced glycation end products in cultured mouse podocytes. Am J Nephrol. 2008;28:1014–22.CrossRefGoogle Scholar
  38. 38.
    Yanagitani K, Imagawa Y, Iwawaki T, Hosoda A, Saito M, Kimata Y, et al. Cotranslational targeting of xbp1 protein to the membrane promotes cytoplasmic splicing of its own mrna. Mol Cell. 2009;34:191–200.CrossRefGoogle Scholar
  39. 39.
    Zeng L, Li Y, Yang J, Wang G, Margariti A, Xiao Q, et al. Xbp 1-deficiency abrogates neointimal lesion of injured vessels via cross talk with the pdgf signaling. Arterioscler Thromb Vasc Biol. 2015;35:2134–44.CrossRefGoogle Scholar
  40. 40.
    Ben Mosbah I, Alfany-Fernandez I, Martel C, Zaouali MA, Bintanel-Morcillo M, Rimola A, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis. 2010;1:e52.CrossRefGoogle Scholar
  41. 41.
    Omar HR, Sprenker C, Karlnoski R, Camporesi EM, Mangar D. Late and very late drug-eluting stent thrombosis in the immediate postoperative period after antiplatelet withdrawal: a retrospective study. Ther Adv Cardiovasc Dis. 2014;8:185–92.CrossRefGoogle Scholar
  42. 42.
    Franck C, Eisenberg MJ, Dourian T, Grandi SM, Filion KB. Very late stent thrombosis in patients with first-generation drug-eluting stents: a systematic review of reported cases. Int J Cardiol. 2014;177:1056–8.CrossRefGoogle Scholar
  43. 43.
    Bechiri MY, Souteyrand G, Lefevre T, Trouillet C, Range G, Cayla G, et al. Characteristics of stent thrombosis in bifurcation lesions analysed by optical coherence tomography [J]. EuroIntervention. 2018;13(18):e2174–e2181.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Hangqi Luo
    • 1
    • 2
  • Changzuan Zhou
    • 3
  • Jufang Chi
    • 1
  • Sunlei Pan
    • 4
  • Hui Lin
    • 1
  • Feidan Gao
    • 1
  • Tingjuan Ni
    • 1
  • Liping Meng
    • 1
  • Jie Zhang
    • 1
  • Chengjian Jiang
    • 1
  • Zheng Ji
    • 1
  • Haitao Lv
    • 1
  • Hangyuan Guo
    • 1
    Email author
  1. 1.Department of CardiologyShaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine)ZhejiangChina
  2. 2.Zhejiang University School of MedicineZhejiangChina
  3. 3.Department of CardiologyWenzhou City Hospital of Traditional Chinese Medicine and Western Medicine CombinedZhejiangChina
  4. 4.Department of Cardiology, The First Affiliated HospitalWenzhou Medical UniversityZhejiangChina

Personalised recommendations